Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507

Barcelona, Spain. 27 March 2025. New study reports that switching patients with chronic wounds to the multi-layered, bordered silicone-coated foam dressing, Mepilex® Border Flex, alongside a clinician educational support programme, resulted in a significant reduction in the number of dressing changes being undertaken and a reduction in dressing-related costs.1
The study, sponsored by Mölnlycke Health Care, and conducted across primary care facilities in Seville, Spain was today presented as an e-poster at the 35th Conference of the European Wound Management Association (EWMA) 2025 in Barcelona, Spain by the principal investigator Dr Andres Roldan Valenzuela, Centro de Salud Mairena del Aljarafe – Cuidad Expo, Seville.
The primary outcome of the study was a statistically significant reduction in the number of dressing changes undertaken, prior to and after the switch from a bordered foam dressing (baseline) to Mepilex® Border Flex; results demonstrated the median number of dressing changes reduced during the study period, from three in a seven-day period to just one.1
Other reported outcomes included:1
Almost all (97%) of the clinicians rated the overall performance of Mepilex® Border Flex to be better than the previously used dressings, while 100% of patients rated Mepilex® Border Flex as ‘good’ to ‘very good’ in terms of overall satisfaction, compared to 65% for the previously used dressings.
Dr Andres Roldan Valenzuela, principal investigator commented “The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.”
For more information, please contact:

Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
The study involved 37 adult patients, aged between 30 and 90+ years presenting with wounds that had not reduced in size by >40-50% in the previous month and had been managed with foam dressing (other than Mepilex® Border Flex), for a minimum of four weeks (baseline). Category 2 pressure ulcers (24.3%) and venous leg ulcers (18.9%) were the most common wound types. Patients in the study had Mepilex® Border Flex applied to their wounds for ≥4 weeks, in conjunction with standard of care.
A broad public–private partnership is now being launched to accelerate the green transition within the Swedish healthcare and life science sector. The initiative aims, through collaboration, to reduce greenhouse gas emissions with the ambition of reaching net zero across the entire value chain by 2045.
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company’s production sites in the Czech Republic.
Healthcare systems worldwide are under pressure to deliver more with less. Fewer resources, tighter budgets, and growing demands. In this article, published in Clinical Services Journal, Eric De Kesel, Chief Operating Officer & Executive Vice President Sustainability and Dr Emma Wright, Chief Medical Officer at Mölnlycke Health Care, explain how Mölnlycke is turning sustainable healthcare from aspiration into practice by connecting performance, people, and planet.
Clinician wellbeing is the cornerstone of sustainable healthcare. Dr Emma Wright, Chief Medical Officer at Mölnlycke Health Care, explains why supporting those who deliver care is essential and how value-based healthcare can unlock better outcomes for patients, healthcare professionals, and healthcare systems.
We are delighted to announce that Mölnlycke was recognised with ‘ESG Transparency Award' by EUPD Research. Mölnlycke achieved the highest excellence level with the total score of 95,5%.
We are proud to play our part in shaping the future of wound care in Europe. Mölnlycke has been elected one of the organisations leading the Wound Care Sector Working Group at MedTech Europe, the industry association representing medical technology across the continent.
Smarter incision care and partnerships are key to enhanced clinical practise and improved patient outcomes.
Gothenburg, Sweden. 12 November 2025. Mölnlycke Health Care, a global leader in MedTech, is the first company to donate a patent to SKF’s groundbreaking digital platform, The Patent Bay – taking bold action to harness collaboration and accelerate innovation in sustainable healthcare.
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.